Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 2Somatostatinoma 1Prostatic Neoplasms 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Growth Hormone-Secreting Pituitary Adenoma 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1

Interventions

pembrolizumab 9avelumab 9Nivolumab 8atezolizumab 4Specimen Handling 4durvalumab 3cemiplimab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3Biopsy 3ALT-803 3talimogene laherparepvec 2fludarabine phosphate 2fludarabine 2domatinostat 2Radiosurgery 2Ipilimumab 2Cisplatin 2Carboplatin 2relatlimab 1oblimersen 1lutetium Lu 177 dotatate 1lenvatinib 1lanreotide 1daromun 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Merkel Cell × Complementary Therapies × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡